KDIGO has published a new commentary in @Kidney_Int highlighting how KDIGO Guidelines and Controversies Conference reports collectively provide guidance across the cardiovascular-kidney-metabolic (#CKM) spectrum. Read the commentary: kdigo.co/KDIGO-2026-CKM-Comm… Framed around the need for a more integrated, patient-centered approach to identifying risk and managing CKM-related conditions, the commentary brings together and delineates KDIGO guidance on chronic kidney disease (CKD), blood pressure, diabetes, lipids, obesity, CKD prevention, and heart failure in CKD. "Heart failure and CKD frequently coexist, share underlying mechanisms, and are too often undertreated when considered in isolation. Improving outcomes requires coordinated care that takes both conditions into account," said Dr. Nisha Bansal, Co-Chair of the forthcoming KDIGO Heart Failure in CKD Guideline. "Diabetes is one of the clearest examples of how CKM risk converges in clinical practice. Increasingly, we have therapies that can address those overlapping risks at the same time, creating an opportunity to reduce cardiovascular risk and slow kidney disease progression in people with diabetes and CKD," said Dr. Ian de Boer, KDIGO Diabetes and CKD Guideline Co-Chair. “CKD is a powerful amplifier of cardiovascular risk, yet it often remains under-detected even in people known to be at high risk,” said Dr. Paul Stevens, KDIGO CKD Guideline Co-Chair. “Earlier recognition of kidney disease, including routine albuminuria testing and accurate staging, is essential to improving outcomes.” Download the commentary: kdigo.co/KDIGO-2026-CKM-Comm…